Faced with the challenge of denting the dominance of Dupixent, Almirall SA has presented positive maintenance data on its investigational atopic dermatitis drug lebrikizumab which could help differentiate the Eli Lilly and Company-partnered therapy when it goes up against Sanofi and Regeneron Pharmaceuticals, Inc.'s mega-blockbuster.
The Spanish group has announced topline results from one-year analyses of the ADvocate 1 and 2 Phase III trials which...